Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients
Version of Record online: 14 AUG 2014
© 2014 The Authors. Pigment Cell & Melanoma Research Published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Pigment Cell & Melanoma Research
Volume 27, Issue 6, pages 1106–1116, November 2014
How to Cite
Mactier, S., Kaufman, K. L., Wang, P., Crossett, B., Pupo, G. M., Kohnke, P. L., Thompson, J. F., Scolyer, R. A., Yang, J. Y., Mann, G. J. and Christopherson, R. I. (2014), Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients. Pigment Cell & Melanoma Research, 27: 1106–1116. doi: 10.1111/pcmr.12290
- Issue online: 23 OCT 2014
- Version of Record online: 14 AUG 2014
- Accepted manuscript online: 4 JUL 2014 01:58AM EST
- Manuscript Accepted: 2 JUL 2014
- Manuscript Received: 17 MAR 2014
- Cancer Institute New South Wales
- National Health and Medical Research Council of Australia
- Australian Research Council Future Fellowship
- CINSW Clinical Research Fellowship
- lymph node metastasis;
- iTRAQ 2DLC-MS/MS;
- protein markers;
Outcomes for melanoma patients with stage III disease differ widely even within the same subcategory. Molecular signatures that more accurately predict prognosis are needed to stratify patients according to risk. Proteomic analyses were used to identify differentially abundant proteins in extracts of surgically excised samples from patients with stage IIIc melanoma lymph node metastases. Analysis of samples from patients with poor (n = 14, <1 yr) and good (n = 19, >4 yr) survival outcomes identified 84 proteins that were differentially abundant between prognostic groups. Subsequent selected reaction monitoring analysis verified 21 proteins as potential biomarkers for survival. Poor prognosis patients are characterized by increased levels of proteins involved in protein metabolism, nucleic acid metabolism, angiogenesis, deregulation of cellular energetics and methylation processes, and decreased levels of proteins involved in apoptosis and immune response. These proteins are able to classify stage IIIc patients into prognostic subgroups (P < 0.02). This is the first report of potential prognostic markers from stage III melanoma using proteomic analyses. Validation of these protein markers in larger patient cohorts should define protein signatures that enable better stratification of stage III melanoma patients.